Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alphamab Oncology's Enterprise Value is €710.60 Mil.
Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.60 Mil. Therefore, Alphamab Oncology's EV-to-FCF for today is -38.21.
The historical rank and industry rank for Alphamab Oncology's EV-to-FCF or its related term are showing as below:
FRA:3NK'
s EV-to-FCF Range Over the Past 10 Years
Min: -59.48 Med: -10.54 Max: 66.74
Current: -38.11
During the past 9 years, the highest EV-to-FCF of Alphamab Oncology was 66.74. The lowest was -59.48. And the median was -10.54.
FRA:3NK's EV-to-FCF is ranked worse than 100% of 321
companies
in the Biotechnology industry
Industry Median: 19.64
vs FRA:3NK: -38.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alphamab Oncology's PE Ratio (TTM) for today is calculated as:
Alphamab Oncology's share price for today is €0.88.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alphamab Oncology EV-to-FCF Related Terms
Alphamab Oncology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alphamab Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's EV-to-FCF falls into.
Alphamab Oncology's current Enterprise Value is €710.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology (FRA:3NK) has a EV-to-FCF of -38.21 as of Aug. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alphamab Oncology and its competitors. According to the industry distribution chart, Alphamab Oncology ranks #999999 out of 321 companies in the Biotechnology industry.
Is Alphamab Oncology's EV-to-FCF too high?
Alphamab Oncology's current EV-to-FCF is -38.21. Based on the distribution chart, Alphamab Oncology ranks #999999 out of 321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #999999 out of 321 companies for EV-to-FCF. This places Alphamab Oncology in the lower half of its industry. The industry median EV-to-FCF is 19.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 19.64, based on 321 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 19.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current EV-to-FCF is -38.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current EV-to-FCF of -38.21. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current EV-to-FCF is -38.21. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current EV-to-FCF is -38.21 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.
Key valuation signals for FRA:3NK:
EV-to-FCF: -38.21
GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for FRA:3NK
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3NK has been successfully added to your 
